智通财经APP讯，卫信康(603676.SH)发布公告，近日，公司全资子公司内蒙古白医制药股份有限公司(以下简称“白医制药”)收到国家药品监督管理局核准签发的复方电解质注射液(V)《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。复方电解质注射液(V)为多种电解质组成的复方制剂，适用于成人，可作为水、电解质的补充源和碱化剂。
公司全资子公司白医制药复方电解质注射液(V)通过一致性评价，将有利于该产品未来的市场销售和市场竞争，并为后续开展仿制药一致性评价积累了宝贵经验。上述事项对公司目前经营业绩不会产生重大影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.